Let's face it, not many of us really expected the big news to appear this week, did we?
The GW management are as keen as we to see the Phase III results published. Had the independent company processing the data been able to produce the results before Christmas by dint of a little extra effort, surely it would have done so?
That the results didn't appear last week surely meant that there was more than a day or two's work still to be done. A day or two's work therefore effectively ruled out this week. Maybe later today? I doubt it.
Maybe next week? Maybe. Conscious of the need to begin to rebuild the company's standing with the investing world, GW's management won't like having missed the target timing of Q4 2006. Looking only a few weeks ahead, 19th. Jan 2006 was the date when GW last issued its prelims. GW won't want to let this year's date slip much later than 19th Jan and the outcome of the two peripheral neuropathic pain trials, inter alia, will greatly influence the tone of the prelims, one way or the other.
GW Pharm stock quotes
GW Pharm stock charts
Follow this thread
